In this study, we systematically tested sigma-2 ligands in vitro and in vivo for relative effectiveness in pancreatic cancer and their relative toxicity in order to identify the best candidate to move into a clinical trial. The gene discussed is AP2S1; the disease is pancreatic neoplasm.